Publications by authors named "K Miyanaga"
Article Synopsis
- * Two specific bacteriophages (vB_kpnM_05 and vB_kpnP_08) were isolated from Thai wastewater and demonstrated effectiveness against a high percentage of drug-resistant K. pneumoniae strains, showing rapid replication and stability under different conditions.
- * A phage cocktail combining these two phages alongside the antibiotic amikacin exhibited enhanced antibacterial activity, preventing bacterial regrowth and highlighting a promising therapeutic approach to combat XDR K. pneumoniae infections.
Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection.
Aye Mya Sithu Shein Dhammika Leshan Wannigama Cameron Hurst Peter N Monk Mohan Amarasiri Kazuhiko Miyanaga
Biomed Pharmacother
October 2023
Given the rise of multidrug-resistant (MDR) Pseudomonas aeruginosa infections, alternative treatments are needed. Anti-pseudomonal phage therapy shows promise, but its clinical application is limited due to the development of resistance and a lack of biofilm penetration. Recently, adjuvants like CaEDTA have shown the ability to enhance the effectiveness of combined antimicrobial agents.
View Article and Find Full Text PDFA Comprehensive Review on Phage Therapy and Phage-Based Drug Development.
Antibiotics (Basel)
September 2024
Article Synopsis
- Phage therapy is gaining attention as a potential solution for treating infections caused by multidrug-resistant bacteria, leveraging naturally occurring viruses called bacteriophages.
- The review covers the historical background, recent advancements, and various applications of phages, including their use in medical fields like vaccine development and cancer treatment.
- Despite its advantages, phage therapy still faces obstacles such as maintaining phage stability, dealing with immune responses, and navigating regulatory challenges for approval.
Article Synopsis
- The study presents a new phagemid-based system that produces CRISPR-Cas13a-loaded antibacterial capsids (AB-capsids) specifically targeting multidrug-resistant Staphylococcus aureus.
- By optimizing phagemid copy numbers, researchers achieved higher yields and purity of AB-capsids, illustrating a direct relationship between phagemid quantity and capsid production.
- The developed AB-capsids effectively eliminate targeted S. aureus strains while leaving non-target strains unharmed, showcasing their potential as effective tools against antibiotic-resistant bacteria.